🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06959459
Starting soon Not applicable

Evaluation of the Safety and Efficacy of Artificial Bone Repair Materials for Repair of Long Bone Defects in the Extremities

NCT06959459 · tracked via the Priya Life Science China tracker
Sponsor
Chinese PLA General Hospital
Phase
Not applicable
Started
2025-05-10
Last updated
2025-05-06

Condition(s) studied

Bone Defects of the Limbs

Investigational drug(s) / intervention(s)

Intervention Group:Use of artificial bone repair materials produced by Changzhou Bone-Renewal Medical Technologies LLC.Control group: Use of β-tricalcium phosphate bioceramics produced by Shanghai Biolu Biomaterials Co., Ltd.

Intervention Group:Use of artificial bone repair materials produced by Changzhou Bone-Renewal Medical Technologies LLC.: Use of artificial bone repair materials produced by Changzhou Bone-Renewal Medical Technologies LLC.

Control group: Use of β-tricalcium phosphate bioceramics produced by Shanghai Biolu Biomaterials Co., Ltd.: Use of β-tricalcium phosphate bioceramics produced by Shanghai Biolu Biomaterials Co., Ltd.

Study summary

Evaluation of the Safety and Efficacy of Artificial Bone Repair Materials for Repair of Long Bone Defects in the Extremities: A Prospective, Randomized Controlled, Single-Blind, Non-Inferiority Clinical Trial

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 years old and ≤ 60 years old, regardless of sex; 2. Cavitary bone defects in the limbs requiring bone grafting treatment; 3. Bone defect volume ≥ 1 cm³ and ≤ 8 cm³, with only one bone defect requiring intervention; 4. Subjects or their legal guardians can understand the study objectives, demonstrate sufficient compliance with the study protocol, and sign the informed consent form. Exclusion Criteria: 1. Open fractures with wound contamination; 2. Repair of infectious bone defects; 3. Structural bone grafting required at the defect site; 4. Osteofascial compartment syndrome in the affected limb scheduled for surgery; 5. Presence of systemic infection, uncontrolled local infection at the surgical site, malignant tumor (including metastatic tumors) at the defect site, osteonecrosis at the defect site, severe nerve/soft tissue/vascular injury at the defect site, confirmed severe malnutrition, or dysfunction/failure of other vital organs; 6. Calcium and phosphorus metabolic abnormalities (calcium/phosphorus levels \> 1.5 times the upper limit of normal values); 7. History of diabetes with fasting blood glucose ≥ 6.1 mmol/L; 8. Coagulation dysfunction (prothrombin time \[PT\] or activated partial thromboplastin time \[APTT\] \> 2 times the upper limit of normal values); 9. Use of chemotherapeutic agents or receipt of radiotherapy within 3 months prior to enrollment; 10. Cumulative use of corticosteroids or growth factors for ≥ 14 days within 1 month prior to enrollment; 11. Long-term use of sedative-hypnotic drugs (continuous use for \> 3 months) or non-steroidal anti-inflammatory drugs (NSAIDs, continuous use for \> 3 months); 12. Known allergy to bovine-derived materials or collagen products; 13. Pregnant or lactating females; 14. Participation in other interventional clinical trials for drugs or medical devices within 1 month prior to enrollment; 15. Any other conditions where investigators, in their professional judgment, deem the subject ineligible to participate in the trial for the subject's safety or benefit.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Chinese PLA General Hosptial Beijing China

More Chinese PLA General Hospital trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06959459 on ClinicalTrials.gov ↗ ← All trials in China